Implementing HIV screening and prevention in low-barrier office-based opioid treatment (OBOT) programs to end the HIV epidemic

Active Grant Awarded Last action

Award ID
R01DA065037
Recipient
Awarding agency
Obligated
$1,352,611

Award facts

Completion date 16% complete
Place of performance
Seattle, WA 98195, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Drug Abuse, awarded the University of Washington's Office of Sponsored Programs (Grant & Contracts Division) $1.352611 million in grant R01DA065037 on February 13, 2026, under the Drug Use and Addiction Research Programs - Research Projects (Assistance Listing 93.DA1). The program supports basic, clinical, translational, and implementation research on drug use, misuse, addiction, overdose, and related health outcomes, including HIV/AIDS.

The project seeks to improve the HIV screening and treatment cascade among patients in four primary care-integrated or co-located office-based opioid treatment (OBOT) programs that offer medications for opioid use disorder at Harborview Medical Center. Aim 1 is a convergent parallel mixed methods assessment that characterizes the HIV testing and prevention cascade and assesses preferences for PrEP modalities and other health services among persons receiving treatment. The source does not describe the work under later aims.

The period of performance runs from the February 13, 2026 award date to an ultimate completion date of November 30, 2030. Work is performed in Seattle, Washington 98195.

Description

Abstract
To end the HIV epidemic (EHE), the united states aims to reduce HIV incidence by 90% by 2030. Achieving elimination of HIV will require increased efforts to screen, treat and prevent HIV among people who use drugs (PWUD). Recommended HIV prevention strategies for PWUD include use of medications for opioid use disorder (MOUD) as well as delivery of pre-exposure prophylaxis (PREP). Nationally and locally, efforts to introduce PREP among PWUD are suboptimal. Yet, our research suggests that PWUD are receptive to newer injectable formulations of PREP, and the recent emergence of a twice-yearly subcutaneous formulation of PREP (LENACAPRAVIR) is a major "game-changer". The landscape of treatment for substance use disorders is also evolving. Office-based opioid treatment (OBOT) programs that offer "low-barrier" MOUD like buprenorphine (including injectable formulations) with other primary care are becoming more widespread and polysubstance use (particularly CO-use of opioids and methamphetamine) among those seeking treatment is now the norm. The focus in these programs is retention and meeting patients' goals for treatment, which may mean reduction in use or safer use but not abstinence. In this context, IT is imperative to offer screening/prevention for HIV. Evidence suggests integration of HIV testing and PREP with OBOT programs is feasible yet in practice such care is not widely implemented. We propose research to improve the HIV screening and treatment cascade among patients cared for in four primary care-integrated, or CO-located, OBOT programs offering MOUD at harborview medical center. In aim #1, we will conduct a convergent parallel mixed methods assessment to characterize the HIV testing and prevention cascade, assess preferences for PREP modalities and other health services among persons receiving treatment in MOUD programs, and assess multi-level barriers and facilitators of service delivery. In aim #2, we will develop, implement and evaluate implementation strategies serially in each clinic working collaboratively with clinic staff. This work will be grounded in the information-motivation-behavioral skills (IMB) and consolidated framework for implementation research (CFIR) frameworks. Reach, effectiveness, adoption, implementation, and maintenance (RE-aim) will be used to evaluate the implementation strategies in all four clinics (N~340) in a pre-post study. The primary effectiveness outcomes are: 1) HIV screening and 2) PREP prescribed. This proposal has the potential to "bend the curve" in HIV prevention in king county, washington, which is one of the U.S. Counties with the highest number of new HIV diagnoses. Furthermore, IT will create a blueprint for other counties, thus contributing to the national EHE efforts. This research proposed is timely and novel as IT coincides with the introduction of highly effective, long-acting injectable (LAI) formulations which can shift the clinical paradigm.

Transactions

Action Obligated Date
Amendment $679,910
Original award $672,701

Quick answers

Who received award R01DA065037?

R01DA065037 was awarded to University Of Washington by National Institute on Drug Abuse (National Institutes of Health) on February 13, 2026.

How much is award R01DA065037 worth?

$1,352,611 has been obligated on R01DA065037.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award